Our Blog discusses the development of rejuvenation biotechnology around the world: progress being made in the field of longevity, the design of medical therapies to cure, reverse and prevent the diseases and disabilities of aging, and much more.
Our content is a blend of popular interest articles – labelled “Easy Reads”, and designed to require no specific background knowledge – as well as more detailed scientific commentaries, labelled as “In-Depth” and aimed towards readers with some grounding in the biological/medical sciences.
Q: When senolytic drugs cause senescent cells to die, other (younger) cells need to divide and take the place of the dead cells. This cell division causes telomere shortening, thus possibly creating new senescent cells. How is it that the process of killing senescent cells is not self-defeating if new senescent cells are being created?
Summary: A new nanotechnology enables the selective targeting of senescent cells; in mice, it dramatically improves an age-related lung disease, and makes cancer chemotherapy safer and more effective. Now the scientists behind it have a startup and are headed toward human testing.
Michael Rae discusses the role of senescent cells in the brain during aging, and how eliminating those cells could prevent diseases like Alzheimer’s and Parkinson’s.
Article by Michael Rae about recent and forthcoming regulatory reforms required to support the testing of new therapies for Alzheimer’s and other age-related diseases.
Question Of The Month #16: Any Rejuvenation Relevance for Roundworm Reproduction? Part of Michael Rae’s regular column from the Foundation’s newsletter.
Alpha-synuclein aggregates are a key form of aging damage in the brain, linked to a spectrum of symptoms in Parkinson’s disease beyond the classic motor symptoms. The first amyloSENS-style immunotherapy to clear this pathology out of the brain was advanced into clinical trials by Austrian biotech firm AFFiRiS AG. Now two more such therapies have entered human testing. Although the trials are in their earliest stages, they bring the hope that this rejuvenation biotechnology will begin preventing and reversing Parkinson’s disease and less specific disorders of aging soon.
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2024 SENS Research Foundation – ALL RIGHTS RESERVED
